Skip to main content
OpenTrials
Completed

NCT Number: NCT03501173

A Study of Participants With Advanced Prostate Cancer in Canada

The purpose of this study is to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostatic Neoplasms Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Urogenital Diseases Urogenital Neoplasms

Age range

21 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Prostate Cancer Centre, Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must have a confirmed diagnosis of adenocarcinoma of the prostate
  • Participant must have prostate cancer, as follows: a) nonmetastatic castrate-resistant prostate cancer (nmCRPC): nmCRPC diagnosis at any time; documented castration resistance per Prostate Cancer Working Group 3 criteria23 (elevated prostate specific antigen [PSA] despite testosterone less than (<) 50 nanograms per deciliter [ng/dL] [<1.7 nano moles per liter {nmol/L}]); Negative for metastases on conventional imaging (computerized tomography, Magnetic resonance imaging, bone scans); Prostate specific antigen doubling time (PSADT) less than equal to (<=) 12 months within the last 6 months or beginning treatment with approved next-generation ARAT for treatment of nmCRPC; b) Metastatic castrate-sensitive prostate cancer (mCSPC): new mCSPC diagnosis in the past 6 months (can be de novo or primary progressive recurrent following local radical therapy); documented metastatic prostate cancer; no more than 12 months of androgen deprivation therapy (ADT) in any setting; no more than 6 months of systemic treatment for mCSPC (example, approved next generation androgen receptor targeted therapy or chemotherapy]); c) Metastatic castrate-resistant prostate cancer (mCRPC): mCRPC diagnosis at any time; documented metastatic prostate cancer; documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nmol/L]); the first treatment for mCRPC was started in the past 6 months or is scheduled to begin; d) mCRPC (treatment-experienced in the nmCRPC or mCSPC setting): mCRPC diagnosis at any time; documented metastatic prostate cancer; documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]); the first treatment for mCRPC clinical state was started in the past 6 months or is scheduled to begin; disease progression occurred while receiving active treatment (androgen receptor-axis therapy [ARAT] or chemotherapy) in the prior nmCRPC or mCSPC clinical state
  • Participant must have a life expectancy of more than 6 months
  • Participant must sign (and/or their legally acceptable representative, if applicable) a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements and/or sponsor policy

Exclusion criteria

  • At the time of screening, patient is currently enrolled in other Janssen sponsored clinical study (any indication) or an interventional clinical trial investigating a non Health Canada approved drug and/or procedure for the treatment and/or monitoring of prostate cancer (Janssen or non-Janssen company sponsored)
  • Participant is currently enrolled in any observational study sponsored or managed by a Janssen company

Treatment and study plan

Standard of care

Other

Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

Primary outcomes

  1. Time to Prostate Specific Antigen (PSA) Progression

    Time frame: Approximately up to 5 years

    Time to PSA progression is defined as the time interval from the date of start of study enrollment to the date of first evidence of PSA progression. In participants whose PSA level has decreased, PSA progression is defined as at least a 25 percent (%) increase from nadir (lowest value including the most recent value prior to study enrollment) and an increase in the absolute value of 2 nanogram per milliliter (ng/mL) or greater, confirmed by a subsequent measurement at least 3 weeks after the increase. In participants whose PSA level has not decreased, PSA progression is defined as at least a 25% increase from the most recent value prior to study enrollment and an increase in the absolute value of 2 ng/mL or greater after 12 weeks.

  2. Time to Radiographic Evidence of Disease Progression

    Time frame: Approximately up to 5 years

    Time to radiographic evidence of disease progression is defined as the time interval from the date of start of study treatment to the date of first appearance of 2 or more new bone lesions on bone scan or enlargement of a soft tissue lesion using the Response Evaluation Criteria in Solid Tumors (RECIST).

  3. Time to Skeletal-Related Events

    Time frame: Approximately up to 5 years

    Time to skeletal-related events is defined as the time interval from the date of start of study treatment to the date of first skeletal-related event.

  4. Time to Death

    Time frame: Approximately up to 5 years

    Time to death is defined as the time interval from the date of start of study enrollment to death.

  5. Number of Participants with Different Primary Causes of Death

    Time frame: Approximately up to 5 years

    The number of participants with different primary causes of death will be reported.

  6. Time to Progression from mCSPC to mCRPC in Participants with mCSPC

    Time frame: Approximately up to 5 years

    In participants with mCSPC, time to progression from mCSPC to mCRPC is defined as the time interval which is either calculated from date when mCSPC was first documented or from the date of start of study treatment, if participant receives treatment for mCSPC to the progression to mCRPC.

  7. Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC

    Time frame: Approximately up to 5 years

    In participants with mCRPC, time from BCR to nmCRPC and nmCRPC to mCRPC will be analyzed retrospectively. BCR is defined as PSA greater than (>)0.2 nanogram per milliliter (ng/mL) after radical prostatectomy and PSA >2 ng/mL above the nadir (lowest value including the most recent value prior to study enrollment) after radical radiotherapy.

  8. Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC

    Time frame: Approximately up to 5 years

    In participants with mCRPC, number of participants having PSA testing from BCR to nmCRPC and nmCRPC to mCRPC will be reported.

  9. Number of Participants with Frequency of Imaging from Time of BCR to nmCRPC and nmCRPC to mCRPC

    Time frame: Approximately up to 5 years

    In participants with non metastatic castrateresistant prostate cancer (nmCRPC), number of participants having imaging from BCR to nmCRPC and mCRPC to nmCRPC will be reported.

  10. PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC

    Time frame: Approximately up to 5 years

    In participants with mCRPC, PSA level at start of ADT will be reported.

  11. PSA Doubling Time (PSADT) at the Detection of Castration Resistance in Participants with mCRPC

    Time frame: Approximately up to 5 years

    In participants with mCRPC, PSADT at the detection of castration resistance will be reported. PSADT is the length of time it takes for a PSA to double based on an exponential growth pattern.

  12. Time from nmCRPC to High-Risk (HR) nmCRPC

    Time frame: Approximately up to 5 years

    Time from nmCRPC to HR nmCRPC is defined as prostate specific antigen doubling time (PSADT) less than or equal to (<=) 10 months.

  13. Time from ADT Initiation to nmCRPC

    Time frame: Approximately up to 5 years

    Time from ADT initiation to nmCRPC will be reported.

  14. Median Absolute prostate specific antigen (PSA) at onset of HR-nmCRPC

    Time frame: Approximately up to 5 years

    Median absolute PSA at onset of HR-nmCRPC will be reported.

  15. Time to Initiation of Subsequent Prostate Cancer Treatment

    Time frame: Approximately up to 5 years

    Time to initiation of subsequent prostate cancer treatment is defined as the time interval from the date of start of study treatment to the date of start of subsequent prostate cancer treatment.

  16. Duration of Each Therapy

    Time frame: Approximately up to 5 years

    Duration for each therapy will be reported for all participants.

  17. Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment

    Time frame: Approximately up to 5 years

    Percentage of participants receiving chemotherapy, other drug treatments, or no drug treatment, will be reported for all participants.

  18. Time to Treatment Initiation

    Time frame: Approximately up to 5 years

    Time to treatment initiation, will be reported for all participants.

  19. Time to Dose Modification

    Time frame: Approximately up to 5 years

    Time to dose modification, will be reported for all participants.

  20. Number of Participants who Switch the Treatment

    Time frame: Approximately up to 5 years

    Number of participants who switch the treatment, will be reported.

  21. Number of Participants who Discontinued the Treatment

    Time frame: Approximately up to 5 years

    Number of participants who discontinued the treatment, will be reported.

  22. Most Common Sequences for Lines of Therapy in Participants with mCRPC

    Time frame: Approximately up to 5 years

    In participants with mCRPC, most common sequences for lines of therapy will be reported.

  23. Number of Participants Retreated with Docetaxel in Participants with mCRPC

    Time frame: Approximately up to 5 years

    In participants with mCRPC, number of participants having retreatment with docetaxel will be reported.

  24. Percentage of Participant with Radiographic Imaging Modality

    Time frame: Approximately up to 5 years

    Percentage of participants with radiographic imaging modality which includes bone scan, magnetic resonance imaging, ultrasound, X-ray will be reported.

  25. Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer

    Time frame: Approximately up to 5 years

    Number of days for which participant was hospitalized for prostate cancer or treatment of prostate cancer, will be reported for all participants.

  26. Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer

    Time frame: Approximately up to 5 years

    Number of visits to emergency department for prostate cancer or treatment of prostate cancer, will be reported for all participants.

  27. Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer

    Time frame: Approximately up to 5 years

    Number of outpatient visits to specialists (urologist, medical oncologist, uro-oncologist, radiation oncologist) involved in management of prostate cancer, will be reported for all participants.

  28. Dates of Genomic or Genetic Testing

    Time frame: Approximately up to 5 years

    Dates of genomic or genetic testing (including dopa-responsive dystonia [DRD]/ homologous recombination repair [HRR]/ breast cancer gene-1 [BRCA1]/ BRCA2/ataxia-telangiesctasia mutated [ATM]/partner and localizer of the BRCA2 gene [PALB2]/ androgen receptor [AR]) will be reported.

  29. Types of Genomic or Genetic Testing

    Time frame: Approximately up to 5 years

    Types of genomic or genetic testing (including DRD/HRR/ BRCA1/ BRCA2/ATM /PALB2/AR) will be reported.

  30. Charlson Comorbidity Index Score

    Time frame: Approximately up to 5 years

    Charlson Comorbidity Index score will be summarized descriptively. The Charlson Comorbidity Index is a 19-item measure assessing comorbid conditions. The total possible score on the Charlson Comorbidity Index ranges from 0 to 37. If a condition is not present, the score for that condition is zero. The higher scores indicate greater comorbidity.

Sponsors and collaborators

Lead sponsor

Janssen Inc.

Industry

Registry information

Official study title

A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada

Acronym: GURC

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Apr 18, 2018
Registry last updated
Jul 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.